RESEARCH Novel high dose rate lip b n

Full list of author information is available at the end of the articleIntroduction Lip and oral cavity cancer is the 15th most common cancer worldwide, and the 15th most common cancer in Europe with more than 300,000 and around 61,400 new cases diagnosed in 2012 respectively (in both cases 2 % of the total) [1]. The incidence in Europe of oral cavity and pharynx cancer in 2012 was 99.6 per 100,000 [2]. In some areas of the world, especially those with a lot of sunshine, the most common sub-site for cancer of the oral cavity is the lip [3]. The most frequent histologic type of lip cancer is Squamous Cell Carcinoma. This is due to the increased exposure to UV radiation in fair-skinned individuals living in regions exposed to sun. Due to its location, lip cancer is usually detected at an early stage and single-modality therapy will usually suf-fice. Surgery or radiotherapy can be utilized, with similar local control and overall survival results [4-6]. The extent of surgical resection depends on tumo